- collapse A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of CAZ-AVI in Children From 3 Months of Age to <18 Years Who are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection
- collapse Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patients with Coronary Heart Disease: A Randomized, Open Label, Crossover Study
- collapse A Single-centre, Randomized, Open-label, Two-period, Cross-over, Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration of the Individual Components in two cohorts of Healthy Chinese Subjects under Fed Conditions
- collapse A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2820 after Administration of Multiple Ascending Doses
- collapse A Randomised, Double-blind, Placebo-controlled Phase IIa Study to Assess the Pharmacodynamics, Safety, and Pharmacokinetics of AZD2624 When Given in Multiple Doses to Females with Polycystic Ovary Syndrome
- collapse An Open-label, Sequential, 3-period Study to Assess the Effects of Cimetidine on the Pharmacokinetics of Naloxegol in Healthy Volunteers.
- collapse An exploratory, double-blind, randomized, placebo controlled, 2 period cross-over, pharmacokinetic/pharmacodynamic, single center study to asses the effect of AZD6140 on respiratory parameters in mild asthma and mild COPD patients age 55 to 75 years
- collapse An exploratory, double-blind, placebo controlled, 2 period cross-over, 3 cohort, single center, pharmacodynamic study to assess the effect of AZD6140 on respiratory parameters in healthy subjects, mild asthmatics and COPD patients age 40 to 70 years.
- collapse A Phase I, Open-label, Multiple-dose, Dose-escalation Study To Assess the Safety, Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies
- collapse A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
